ストックスクリーナーアプリを入手
158.44
0.25%
-0.39
プレマーケット:
158.66
0.22
+0.14%
前日終値:
$158.83
開ける：
$156.91
24時間の取引高:
2.09M
Relative Volume:
1.17
時価総額：
$301.15B
収益：
$54.66B
当期純損益:
$13.58B
株価収益率:
22.58
EPS:
7.0171
ネットキャッシュフロー:
$16.05B
1週間 パフォーマンス:
+1.47%
1か月 パフォーマンス:
+0.54%
6か月 パフォーマンス:
+6.56%
1年 パフォーマンス:
+35.85%
1日の値動き範囲:
$156.46
$158.55
1週間の範囲:
$154.44
$160.34
52週間の値動き範囲:
$112.34
$170.46
Novartis Ag Adr Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
158.44 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
LLY
Lilly Eli Co
|
1,154.97 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.82 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
257.41 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.79 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-11 | アップグレード | Argus | Hold → Buy |
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2026-01-06 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-12-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-09-12 | ダウングレード | Goldman | Neutral → Sell |
| 2025-08-08 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | ダウングレード | UBS | Buy → Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Underweight |
| 2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
| 2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-12-05 | アップグレード | Stifel | Hold → Buy |
| 2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 再開されました | Citigroup | Buy |
| 2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
| 2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 開始されました | Bernstein | Mkt Perform |
| 2021-03-10 | ダウングレード | Argus | Buy → Hold |
| 2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-09-10 | アップグレード | UBS | Neutral → Buy |
| 2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
| 2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-04-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
| 2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
Weekly Recap: Novartis Q2 net sales up ~1–3% and Entresto 50% sales drop - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Revenue Breakdown – BCBA:NVSB - TradingView
Novartis AG Sponsored ADR Revenue Breakdown – SWB:NOTA - TradingView
Novartis stock trades steady as Q1 2026 revenue grows and Cosentyx expansion supports outlook - Ad-hoc-news.de
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline - Sahm
Novartis stock trades steady as Q2 2026 results highlight solid specialty medicines growth - Ad-hoc-news.de
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating - The Motley Fool
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - GlobeNewswire Inc.
Novartis ADR earnings beat by $0.23, revenue topped estimates - Investing.com Canada
Novartis AG Stock (NVS) Moved Up by 3.42% on Jul 21: Key Drivers Unveiled - TradingKey
Novartis second quarter sales rise 3% to $14.4 billion - grafa.com
Earnings call transcript: Novartis tops Q2 2026 forecasts as shares rise - Investing.com
Novartis (NYSE: NVS) Q2 2026: key drugs surge while net debt jumps - Stock Titan
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US - Sahm
NVS Stock Quote Price and Forecast - CNN
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval - Sahm
Novartis stock holds steady as pipeline and global reach underpin long-term growth - Ad-hoc-news.de
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis highlights drug pipeline strength as global healthcare demand grows - Ad-hoc-news.de
ETFs Investing in Novartis AG Sponsored ADR Stocks - TradingView
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Sahm
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - Barchart.com
Why Does Novartis AG-Sponsored ADR (NYSE:NVS) Track the NYSE Composite? - Kalkine Media
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout - ChartMill
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition - sharewise.com
Novartis to acquire Myricx Bio for $1.5 billion - grafa.com
10 Newly Overvalued Stocks this Week - Morningstar
What's Going on with Vera Therapeutics Stock on Monday? - Sahm
NVSNovartis AG ADR Options - Finviz
NOTA Forecast — Price Target — Prediction for 2027 - TradingView
Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States - Sahm
Novartis outlines growth path as pipeline and US exposure support long-term story - ad-hoc-news.de
Novartis stock holds steady after EAACI Rhapsido update. US trading stays in view. - Ad-hoc-news.de
Novartis consensus picture on SIX, analysts keep a neutral view on the stock - Ad-hoc-news.de
Novartis opens the week with a cautious sector backdrop, shares in focus alongside Roche - AD HOC NEWS
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVS) - TradingView
Price to earnings forward of Novartis AG Sponsored ADR – MUN:NOTA - TradingView
Novartis oncology partnership with Antares, shares trade near analyst targets - AD HOC NEWS
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSC) - TradingView
Novartis focuses on oncology pipeline, shares track SMI pharma peers - ad-hoc-news.de
907122 Forecast — Price Target — Prediction for 2027 - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSD) - TradingView
Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR Actuals & Estimates (BMFBOVESPA:N1VS34) - TradingView
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
0.44%
0.06%
大文字化:
|
ボリューム (24 時間):